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Background and Purpose: This study compared the cognitive effects of 1 year of treatment with lamotrigine 
(LTG) and oxcarbazepine (OXC) in epilepsy patients. 
Methods: This retrospective study investigated 60 epilepsy patients undergoing neuropsychological tests who 
were either newly diagnosed or untreated in the preceding 6 months. The cognitive function in 30 patients receiving 
LTG monotherapy and 30 age-matched patients receiving OXC monotherapy was compared after 1 year. The 
neuropsychological scores at baseline and all of the epilepsy-relevant variables except seizure type did not differ 
between the groups. The mean daily dosages of LTG and OXC at 1 year were 93 mg and 825 mg, respectively. 
Results: The posttreatment list-learning performance was better in the LTG group than in the OXC group 
(p<0.05). The incidence of cognitive complaints did not differ between the two groups. The list-learning performance 
and Trail Making Test scores were better in each group after treatment. 
Conclusions: LTG and OXC monotherapies have similar, slightly beneficial effects on cognitive function, and are 
probably not harmful.
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INTRODUCTION
Cognitive and behavioral deficits are more common in 
patients with epilepsy than in the general population.
1 A 
significant proportion of patients with epilepsy are at 
increased risk of cognitive impairment due to various 
factors.
1 Moreover, antiepileptic drugs (AEDs) can cause 
adverse cognitive effects.
2,3 AEDs exert a dosage- 
dependent effect on cognitive function, and AED poly-
therapy can frequently result in worse cognitive side 
effects. The cognitive effects of traditional AEDs in 
monotherapy and as adjuncts to other drugs are re-
latively well established,
3 but the differential effects of 
new AED monotherapies are less clear.
3 
Lamotrigine (LTG) is an AED with wide spectrum 
efficacy in the treatment of partial seizures and primary 
and secondary generalized seizures.
4 However, the 
cognitive effects of LTG in patients with epilepsy are 
not easy to interpret. For example, it is difficult to 
isolate the genuine effects of LTG from the cognitive 
changes caused by changes in seizure frequency. Even in 
patients with a low seizure frequency, it appears to be 
difficult to interpret the cognitive effects of LTG because Journal of Clinical Neurology: Vol. 3, No. 1, 2007
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LTG may suppress epileptiform EEG discharges, which 
also may result in changes to cognitive function.
5,6
Studies comparing LTG with other AEDs in healthy 
volunteers have revealed fewer side effects on cognitive 
function for LTG than for carbamazepine (CBZ), 
valproate (VPA), and topiramate.
6–9 Moreover, short- 
term treatment of normal volunteers with a low dosage 
of LTG resulted in improved cognitive activation as 
quantified by simple reaction-time measurements.
6  Thus, 
further neuropsychological studies are needed to elu-
cidate the cognitive effects of LTG in patients with 
epilepsy, including in those on longer maintenance 
periods.
Oxcarbazepine (OXC) is a novel AED that is 
chemically related to CBZ and is approved as an initial 
or add-on treatment for partial seizures.
10 Two European 
studies have evaluated its cognitive effects in adult 
epilepsy patients.
10,11  In one of these, newly diagnosed 
patients received OXC or other AEDs as a monotherapy 
for 4 months. Compared with baseline, OXC-treated 
patients improved in 1 of 20 cognitive tasks and 
worsened in none, and the results were similar in 
patients receiving CBZ, VPA, phenobarbital, or 
phenytoin (PHT) monotherapy.11In the other study, 
which was a double-blind comparison of OXC with 
PHT monotherapy in newly diagnosed patients,
12  no 
differences between OXC and PHT were detected in any 
of the seven cognitive variables measured at any of the 
time points. We have also previously investigated the 
cognitive effects of OXC in epilepsy patients using 
neuropsychological tests and event-related potentials, and 
found no negative effects on cognition after 1 year of 
treatment with OXC.
13 The results of these studies 
suggest that OXC does not affect cognitive function 
in epilepsy patients.
This study compared the cognitive effects of 1 year 
of treatment with LTG and OXC in epilepsy patients. 
The results of various cognitive tests and subjective 
complaints were compared at baseline and after 1 year 
of medication between the two groups. 
MATERIALS AND METHODS
1. Subjects 
Six years ago, our epilepsy clinic began to study the 
cognitive effects of AEDs on epilepsy patients, routinely 
conducting cognitive evaluations on the basis of self- 
reporting, subjective complaints, and various cognitive 
tests before and after treatment with AEDs. Symptom 
severity after medication was divided into four grades: 
grade 0, no symptoms; grade 1, mild and intermittent 
cognitive problems, sometimes forgotten; grade 2, mo-
derate and steady cognitive deficits, sometimes dis-
comforting; and grade 3, severe cognitive deficits 
making the patient unable to continue medication. 
Cognitive tests were performed three times in each 
subject: at baseline, and 1 year and 3 years after starting 
medication. EEGs were measured in all patients when 
they entered the study and also at the time of the second 
and third cognitive tests. An MRI study of the brain was 
performed once in each patient during the study. 
Our epilepsy neuropsychological database contained 
more than 600 cases, from which we randomly selected 
cases that conformed with all of the following criteria: 
(1) LTG or OXC monotherapy with follow-up cognitive 
evaluations performed at 1 year, (2) newly diagnosed 
epilepsy or epilepsy that had not been treated with 
AEDs within at least the previous 6 months, (3) no 
progressive neurological disorders, head injury, mental 
retardation, alcohol or drug abuse, ongoing use of 
any centrally acting medications, severe psychiatric 
problems, or other severe medical disorders, and (4) no 
cognitive complaints at baseline even in the absence of 
the above insults. 
A total of 30 patients for the LTG group and 30 
age-matched patients for the OXC group who met the 
above criteria were collected from the database. The 
characteristics of the patients are listed in Table 1. The 
daily mean AED dosages at 1 year were 93 mg for LTG 
and 825 mg for OXC. The monthly seizure rate de-
creased significantly in both groups after AED medi-
cation. None of the epilepsy-relevant variables except 
seizure type differed between the groups. Seo JG, et al. Cognitive Effects of Lamotrigine and Oxcarbazepine
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Table 1. Patient characteristics
LTG (n=30) OXC (n=30) Significance
a
Age, y, mean (range) 26.4 (15-53) 28.7 (14-53)  NS*
Sex, % male 43 53 NS
Education, %
graduate primary or middle school 13 20 NS
graduate high school or college 87 80 NS
Seizure type, %  P < 0.01
Partial 33 77
Generalized  67 23
Duration of epilepsy, y, mean (range) 3.6 (0.1-20) 3.1 (0.1-20) NS
Newly diagnosed epilepsy, within 3 months, % 73 60 NS
Presence of brain pathology in MRI, % 17 30 NS
Dose at 1 year, mg/day, mean (range) 93 (50-200) 825 (600-1,500)
Seizure rate for recent 3 months, seizures/month
Baseline 0.5 (0.3-3) 1.7 (0.3-20) NS
At 1 year 0.1
‡(0-1) 0.5
†(0-8) NS
Abnormality of EEG, %
Baseline 43 57 NS
At 1 year 23 33 NS
LTG; lamotrigine, OXC; oxcarbazepine
aFisher exact tests and t tests for independent samples (two-sided), *Nonsignificant, P > 0.05, 
†P < 0.05, 
‡P < 0.01, comparing 
with baseline
2. Neuropsychological tests
All cognitive tests were administered in a sound- 
attenuated, temperature-controlled room by a single 
examiner. According to the literature and our own 
clinical experience, we selected two cognitive measures 
that were particularly sensitive to AED-induced cog-
nitive impairment. We assessed memory function 
through list learning, immediate and delayed word recall, 
word recognition, and visual reproduction based on the 
Memory Assessment Scale, which was obtained from 
Psychological Assessment Resources.
14 We assessed 
attention deficit by using digit spans (forward and 
backward) from the Wechsler Memory Scale–Revised.
15 
We examined attention, visuomotor tracking abilities, 
and mental flexibility with the Trail Making Test (TMT) 
from the Halstead-Reitan Battery.
16 We studied verbal 
fluency using semantic fluency tests from the Boston 
Diagnostic Aphasia Examination–Third Edition.
17 Testing 
sessions lasted about 30 minutes. If seizures occurred 
during a neuropsychological examination, the test was 
suspended and the data discarded. 
3. Study design 
We evaluated the differences in cognitive function 
between the LTG and OXC groups at 1 year based on 
subjective complaints and cognitive tests. We also 
investigated the changes in cognitive scores from 
baseline to those after 1 year of medication in each 
group. We compared cognitive results with the patient 
characteristics, the clinical features of the epilepsy, EEG 
abnormalities, neuroradiological findings, and daily AED 
dosage. To assess the effects of daily AED dosage on 
cognitive function, the frequency of cognitive complaints 
and the change in cognitive scores from baseline to 
those after 1 year of medication (at each target dosage) 
were compared. 
4. Statistical analysis 
Higher scores indicated better performance on all 
cognitive tests except the TMT (parts A and B), for 
which higher scores indicate a poorer performance 
because the time required was defined as the dependent Journal of Clinical Neurology: Vol. 3, No. 1, 2007
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Table 2. Neuropsychological outcome  
LTG (n=30) OXC (n=30)
Measure Test session mean (SD) mean (SD) Significance
a
List learning  Baseline  61.7 (6.6)   59.3 (7.3)  NS*
At 1 year   65.0 (4.3)
‡    61.5 (7.2)
†   P < 0.05
Immediate word recall Baseline   11.5 (1.1)  11.1 (1.4) NS
At 1 year   11.6 (0.7)  11.2 (1.1) NS
Delayed word recall Baseline  11.5 (1.2)  11.1 (1.2) NS
At 1 year  11.6 (0.6)  11.3 (1.0) NS
Word recognition Baseline  12.0 (0.0)  11.9 (0.3) NS
At 1 year  12.0 (0.0)  12.0 (0.0) NS
Visual reproduction Baseline   8.9 (1.4)   8.3 (2.1) NS
At 1 year   8.8 (1.5)   8.3 (1.6) NS
Digit span, forward Baseline   9.1 (2.3)   8.5 (2.4) NS
At 1 year   8.9 (2.0)   8.3 (2.5) NS
Digit span, backward Baseline   6.9 (2.3)   7.1 (2.7) NS
At 1 year   7.0 (2.4)   7.4 (2.6) NS
Trail Making Test, part A
Time (sec) Baseline  30.8 (8.7)   29.7 (17.1) NS
At 1 year   24.4 (7.7)
‡    24.4 (13.8)
† NS
Error no. Baseline   0.2 (0.5)   0.1 (0.3) NS
At 1 year   0.2 (0.6)   0.1 (0.2) NS
Trail Making Test, part B
Time (sec) Baseline   75.4 (29.1)   78.2 (48.7) NS
At 1 year   72.3 (29.8)    66.4 (39.5)
† NS
Error no. Baseline   0.9 (1.1)   0.6 (0.9) NS
At 1 year   0.8 (0.9)   0.4 (0.7) NS
Verbal fluency Baseline  17.0 (5.6)  15.1 (4.6) NS
At 1 year   17.3 (5.2)  16.7 (5.2) NS
LTG; lamotrigine, OXC; oxcarbazepine
at test for independent samples (two-sided), *Nonsignificant, P > 0.05, 
†P < 0.05, 
‡P < 0.01, paired t test for comparison with baseline 
Higher scores indicate better performance except for Trail Making Test
measure for these tests. The data for continuous va-
riables are expressed as mean±SD values, and the data 
for categorized variables are expressed as frequencies. 
We used paired t-tests to compare cognitive scores 
before and after medication in the same subject. We also 
used  t-tests for independent samples to compare the 
cognitive scores between the LTG and OXC groups. 
Fisher’s exact test was used for the categorized 
variables. A one-way analysis of variance for inde-
pendent samples was used for comparing differences 
in cognitive scores before and after AED medication 
among groups with different AED dosages. Bonferroni 
correction was employed for post-hoc comparisons, with 
the  α level set at 0.05.
RESULTS
1. Intra- and intergroup differences 
Table 2 indicates that in the LTG group, the list- 
learning performance and score for TMT part A were 
better at 1 year than at baseline (both p<0.01). In the 
OXC group, the list-learning performance and scores for 
TMT parts A and B were also better at 1 year than at 
baseline (both p<0.05).
The results of several neuropsychological tests 
performed at baseline were compared between the 
patient groups. As indicated in Table 2, the initial 
cognitive scores did not differ significantly. However, Seo JG, et al. Cognitive Effects of Lamotrigine and Oxcarbazepine
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after 1 year of treatment, the list-learning performance 
was better in the LTG group than in the OXC group 
(p<0.05). 
The incidence of cognitive complaints did not differ 
significantly between the OXC group (7/30 patients, 
23%) and the LTG group (6/30 patients, 20%). Twenty 
percent of the patients taking LTG were described has 
having only a memory deficit, which was categorized as 
grade 1. Twenty percent of patients taking OXC 
complained of memory deficit, with 3% complaining of 
an attention or concentration deficit, which were also 
categorized as grade 1.
2. Correlation analyses
The frequency of cognitive complaints and changes in 
neuropsychological test scores in the LTG and OXC 
groups were not correlated with patient characteristics, 
clinical features of epilepsy, EEG abnormalities, neuro-
radiologic findings, or daily AED dosage.
DISCUSSION
This was a comparative study that compared the 
cognitive effects of 1 year of treatment of LTG and 
OXC in epileptic patients. The posttreatment list-learning 
performance was better in the LTG group than in the 
OXC group. The incidence of cognitive complaints did 
not differ between the two groups. The list-learning 
performance and TMT scores were better in each group 
after AED treatment.
Even though several studies have provided clinical 
evidence of the effects of LTG on cognitive function, 
their findings were limited by the small numbers of 
patients, the absence of baseline cognitive assessments, 
and the presence of intractable seizures, irregular 
dosages, concurrent or previous AED use, and brain 
pathology.
6–9,18,19 To minimize these confounding factors, 
the ideal cognitive study should administer an AED 
monotherapy to patients with newly diagnosed epilepsy, 
with cognitive assessments performed at baseline, before 
treatment, and at a point when the patients have been in 
steady-state treatment at a fixed clinical dosage.
20,21  Our 
cases met these criteria, and we also reduced several of 
the confounding factors in epilepsy. Moreover, all of our 
patients were receiving a monotherapy, many of them 
were newly diagnosed and nonlesional, and most of 
them were well controlled by AED.
Comparative methodologies are also popular in studies 
of the cognitive effects of AEDs, in which these effects 
of the drug under investigation are compared with those 
of other widely prescribed drugs. Since our study was 
retrospective, it did exhibit some inevitable methodo-
logical limitations as a comparative study. Patients were 
selected from our neuropsychological database according 
to a set of self-generated inclusion criteria, and thus 
selection bias cannot be excluded. Therefore, multi-
center, double-blind, placebo-controlled studies still need 
to be performed.
The reasons for the positive effects of AEDs on 
cognition relate to their therapeutic effects on epilepsy, 
leading to a reduction in psychosocial problems or the 
stimulation of psychomotor functioning.
1–3,22 Animal 
experiments suggest that LTG has no effect on either the 
induction or the maintenance of long-term potentiation 
of memory function,
23  and may even protect against 
excitotoxic and ischemic insults.
24 Because LTG does 
not primarily act on GABAergic neurotransmission, it 
may be associated with less cognitive and behavioral 
impairment.
25 Furthermore, LTG has demonstrated 
efficacy in bipolar disorder in terms of preventing or 
delaying mood episodes in depression, which is a 
mainstay psychosocial problem in epilepsy.
26 Therefore, 
LTG may also had positive effects on cognition. 
Unfortunately, we did not conduct neuropsychological 
tests related to mood state in our study, and hence were 
unable to assess mood changes that were directly attri-
butable to LTG. Another possible reason for improved 
cognitive scoresis the use of low-dosage LTG in our 
patients. We administered low-dosage LTG for mono-
therapy (50-200 mg/day) in patients with newly dia-
gnosed epilepsy or epilepsy that had not been treated 
with AEDs. Because cognitive adverse effects of AEDs 
have been related to the administration of higher 
dosages, our use of low-dosage LTG may have 
contributed to the improved cognitive scores. However, 
we found no correlation between changes in cognitive Journal of Clinical Neurology: Vol. 3, No. 1, 2007
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scores and the dosage used. The last possible reason for 
cognitive improvement is the existence of practice 
effects, despite the long test-retest interval used in this 
study. However, only two of the ten categories in the 
cognitive tests were significantly changed at retest, and 
practice effects would have been evident in most of the 
measures used.
27 Testing a control group at the same 
time intervals might have solved this problem.
Treating epilepsy may reduce the cognitive and 
behavioral impairments by stopping or decreasing the 
seizures, but it may also induce undesirable effects on 
cognition and behavior. The optimal epilepsy treatment 
involves using an AED that best controls the patient’s 
seizures with the fewest side effects. Cognitive effects 
are only one factor in AED selection, since AED- 
induced cognitive impairments may be outweighed by 
the potential for seizure control and overall improvement 
in quality of life. The harmful cognitive effects of AEDs 
are especially important to those who require maximal 
cognitive efficiency for their job, school, or daily 
activities. Our study demonstrated that LTG and OXC 
monotherapies have similar, slightly beneficial effects on 
cognitive function, and are probably not harmful after 1 
year of medication. However, future prospective studies 
are needed to confirm the cognitive effects of LTG and 
OXC in epilepsy patients. 
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